TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.
Bo Li(Affiliated Hospital of Southwest Medical University), Song Su(Affiliated Hospital of Southwest Medical University), Fangyi Peng(Southwest Medical University), Hao Tang(Hainan University), Xiaoli Yang(Guilin Medical University)
Cited by 0
Related Papers
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2020|421
HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry
|Nature Metabolism|2020|304
The Hepatitis B Virus X Protein Disrupts Innate Immunity by Downregulating Mitochondrial Antiviral Signaling Protein
|The Journal of Immunology|2010|235
Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma
|European Urology|2018|152
Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification
|International Journal of Cardiology|2013|107